UNC13B — UNC13 Homolog B (Munc13-2)

title: UNC13B — UNC13 Homolog B (Munc13-2)
category: gene

UNC13B — UNC13 Homolog B (Munc13-2)

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Munc13-2 (Munc13 Homolog B)</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>UNC13B</td></tr>
<tr><td><strong>Full Name</strong></td><td>UNC13 Homolog B</td></tr>
<tr><td><strong>Protein Name</strong></td><td>Munc13-2 (Mammalian uncoordinated 13-2)</td></tr>
<tr><td><strong>Chromosome</strong></td><td>9p13.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[23026](https://www.ncbi.nlm.nih.gov/gene/23026)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[607698](https://www.omim.org/entry/607698)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000075643</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9Y5S4](https://www.uniprot.org/uniprot/Q9Y5S4)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>Synaptic vesicle priming protein, C1 domain-containing</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Epilepsy](/diseases/epilepsy), Schizophrenia</td></tr>
</table>
</div>

Overview

title: UNC13B — UNC13 Homolog B (Munc13-2)
category: gene

UNC13B — UNC13 Homolog B (Munc13-2)

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Munc13-2 (Munc13 Homolog B)</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>UNC13B</td></tr>
<tr><td><strong>Full Name</strong></td><td>UNC13 Homolog B</td></tr>
<tr><td><strong>Protein Name</strong></td><td>Munc13-2 (Mammalian uncoordinated 13-2)</td></tr>
<tr><td><strong>Chromosome</strong></td><td>9p13.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[23026](https://www.ncbi.nlm.nih.gov/gene/23026)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[607698](https://www.omim.org/entry/607698)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000075643</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9Y5S4](https://www.uniprot.org/uniprot/Q9Y5S4)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>Synaptic vesicle priming protein, C1 domain-containing</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Epilepsy](/diseases/epilepsy), Schizophrenia</td></tr>
</table>
</div>

Overview

UNC13B encodes Munc13-2 (Mammalian uncoordinated 13-2), a critical presynaptic protein that plays an essential role in neurotransmitter release. Munc13-2 is one of three Munc13 isoforms (Munc13-1, Munc13-2, Munc13-3) that function as master organizers of synaptic vesicle priming, the process that prepares synaptic vesicles for calcium-triggered fusion with the presynaptic membrane.[@varoqueaux2005] Located on chromosome 9p13.3, the UNC13B gene produces multiple protein isoforms through alternative splicing, with the full-length isoform comprising 1,735 amino acids and a molecular weight of approximately 200 kDa.

The discovery of Munc13 proteins emerged from studies in mice, where mutations in the UNC13 gene family were found to cause severe deficits in synaptic transmission. The name "uncoordinated" reflects the phenotypic consequences of Munc13 loss—mice lacking Munc13-1 die shortly after birth due to inability to breathe, while those with reduced Munc13 function exhibit impaired motor coordination. These findings established Munc13 proteins as fundamental components of the synaptic vesicle release machinery.

Beyond its essential role in baseline neurotransmitter release, Munc13-2 is uniquely positioned to modulate synaptic plasticity through its regulation of short-term plasticity, including facilitation and depression.[@stephens2018] The protein's structural features, including a C1 domain that binds diacylglycerol (DAG) and phorbol esters, allow it to integrate synaptic activity signals and adjust release probability accordingly. This plastic regulatory capacity im[@consalez2016]plicates Munc13-2 in cognitive processes including learning and memory, and its dysfunction has been increasingly recognized in neurodegenerative and psychiatric disorders.

Gene Structure and Protein Architecture

Genomic Organization

The UNC13B gene spans approximately 70 kb on chromosome 9p13.3 and comprises 37 exons. The gene exhibits complex alternative splicing that generates multiple isoforms with distinct functional properties:

| Isoform | Structure | Expression Pattern |
|---------|-----------|--------------------|
| Munc13-2 (full-length) | Contains C1, C2B, MUN domain | Ubiquitous, high in cortex |
| Munc13-2B (short) | Lacks C1 domain | Neuron-specific |
| Munc13-2C | Alternative C-terminus | Limited distribution |

The promoter region of UNC13B contains elements responsive to neuronal activity, allowing activity-dependent regulation of expression. Transcription factors including CREB (cAMP response element-binding protein) regulate UNC13B transcription in response to synaptic activity.

Protein Domain Structure

Munc13-2 possesses a multidomain architecture that enables its diverse functions:

Splice Variants and Functional Implications

The UNC13B gene produces multiple splice variants with distinct functional properties:

• Munc13-2 (full-length): Contains all domains including the C1 domain, allowing phorbol ester-responsive regulation
• Munc13-2B: Lacks the C1 domain, resulting in reduced activity-dependent modulation
• Munc13-2C: Contains alternative C-terminus with potentially different interaction partners

Molecular Function in Synaptic Transmission

Synaptic Vesicle Cycle Overview

Neurotransmitter release at chemical synapses proceeds through a series of coordinated steps known as the synaptic vesicle cycle:

Munc13-2 plays essential roles in the priming step, without which vesicles cannot undergo calcium-triggered fusion.

Munc13-2 in Synaptic Vesicle Priming

Synaptic vesicle priming refers to the process by which vesicles transition from a docked state to a fusion-competent state that can respond to calcium influx. Munc13 proteins are master regulators of this process:

Mechanisms of priming:

The essential nature of Munc13-2 in priming is demonstrated by the complete loss of synchronous neurotransmitter release in Munc13-1/Munc13-2 double knockout mice, while partial loss causes severe synaptic deficits.

SNARE Complex Formation

Munc13-2 directly promotes SNARE complex assembly through multiple mechanisms:

• Syntaxin recruitment: Munc13-2 helps recruit and organize syntaxin at the active zone
• SNARE assembly: The MUN domain facilitates SNARE complex formation
• SNARE stabilization: Munc13-2 prevents premature SNARE complex disassembly

Regulation by Second Messengers

Munc13-2 is regulated by several second messenger pathways:

| Second Messenger | Effect on Munc13-2 | Functional Consequence |
|------------------|-------------------|----------------------|
| Diacylglycerol (DAG) | C1 domain binding | Enhanced priming |
| Phorbol esters | C1 domain binding | Dramatic release enhancement |
| Calcium | C2B domain binding | Activity-dependent modulation |
| Calmodulin | C-terminal binding | Activity-dependent regulation |

The phorbol ester response is particularly notable—phorbol esters bind to the C1 domain and dramatically enhance neurotransmitter release, demonstrating that Munc13-2 can dynamically modulate synaptic strength in response to signaling pathways.

Expression Patterns and Cellular Localization

Brain Region Distribution

Munc13-2 is expressed throughout the central nervous system with regional variation:

| Brain Region | Expression Level | Cell Types |
|--------------|-------------------|------------|
| Cerebral Cortex | Very High | Layer 2/3 and layer 5 pyramidal neurons |
| Hippocampus | Very High | CA1-CA3 pyramidal neurons, dentate granule cells |
| Cerebellum | High | Purkinje cells, granule cells |
| Striatum | High | Medium spiny neurons |
| Thalamus | Moderate-High | Relay neurons |
| Brainstem | Moderate | Various nuclei |
| Spinal Cord | High | Motor neurons, interneurons |

The high expression in hippocampus and cortex reflects the importance of Munc13-2 in circuits involved in learning and memory.

Cellular and Subcellular Localization

Within neurons, Munc13-2 exhibits presynaptic specialization:

• Presynaptic terminals: Highest concentration at synaptic active zones
• Active zone membrane: Associated with the electron-dense active zone matrix
• Synaptic vesicles: Partially associated with synaptic vesicle pools
• Axon initial segment: Lower levels in initial segment
• Dendrites: Minimal dendritic localization

Developmental Expression

Munc13-2 expression changes during development:

• Embryonic: Low expression, immature synapses
• Early postnatal: Rapid increase as synaptogenesis occurs
• Adult: Sustained high expression
• Aging: Variable changes, some decrease in aged brain

Role in Synaptic Plasticity

Short-Term Plasticity

Munc13-2 plays a critical role in regulating short-term synaptic plasticity, the activity-dependent changes in release probability that occur over milliseconds to seconds:

Facilitation: When synapses receive closely spaced stimuli, release probability increases. Munc13-2 contributes to facilitation through:

• Residual calcium effects on Munc13-2
• Phosphorylation-dependent modulation
• Activity-dependent recruitment of Munc13-2

• Vesicle depletion at high release probability synapses
• Munc13-2 availability limits recovery from depression

Long-Term Plasticity

While Munc13-2 is best characterized for its role in short-term plasticity, it also contributes to longer-term synaptic changes:

• LTP induction: Munc13-2 may be involved in the molecular events underlying long-term potentiation
• LTD expression: Changes in Munc13-2 availability could contribute to long-term depression
• Homeostatic plasticity: Munc13-2 levels adjust in response to chronic activity changes

Activity-Dependent Regulation

Munc13-2 function is modulated by synaptic activity:

• Phosphorylation: Kinases including PKC phosphorylate Munc13-2
• Calcium/calmodulin: Calmodulin binding to Munc13-2 provides calcium-dependent regulation
• DAG production: Active synapses produce DAG that activates Munc13-2 via the C1 domain
• Protein-protein interactions: Activity-dependent changes in Munc13-2 interactions modulate its function

Disease Associations

Alzheimer's Disease

Alzheimer's disease (AD) is characterized by progressive cognitive decline due to synaptic loss and neuronal death. Munc13-2 dysfunction contributes to AD pathogenesis through multiple mechanisms:

Evidence for Munc13-2 involvement in AD:

• Altered expression in AD brain tissue
• Impaired phorbol ester response in AD models
• Synaptic plasticity deficits in AD mouse models
• Genetic variants may modify AD risk

Parkinson's Disease

Parkinson's disease (PD) involves progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Munc13-2 plays important roles in dopaminergic neurotransmission:

Connections to PD pathology:

• Alpha-synuclein affects synaptic vesicle dynamics
• Mitochondrial dysfunction impacts presynaptic function
• LRRK2 mutations may affect synaptic transmission
• Munc13-2 expression changes in PD models

Epilepsy

Epilepsy involves abnormal excessive neuronal activity that results in recurrent seizures. Munc13-2 dysfunction may contribute to epileptogenesis:

Evidence from studies:

• Altered Munc13-2 expression in epileptic tissue
• Genetic variants associated with epilepsy risk
• Animal models show Munc13-2 involvement in seizure phenotypes

Schizophrenia and Psychiatric Disorders

Munc13-2 has been implicated in schizophrenia and other psychiatric conditions:

Therapeutic Implications

Targeting Synaptic Vesicle Priming

Munc13-2's central role in neurotransmitter release makes it a potential therapeutic target:

For Neurodegenerative Diseases

Therapeutic strategies for AD and PD:

• Neuroprotective agents: Protect Munc13-2 from pathological insults
• Synaptic enhancers: Improve synaptic function despite pathology
• Combination approaches: Target multiple aspects of synaptic dysfunction

For Epilepsy

Potential antiepileptic strategies:

• Normalize release probability: Modulate Munc13-2 function
• Reduce hyperexcitability: Decrease excessive neurotransmitter release
• Network stabilization: Restore proper plasticity mechanisms

Research Methods

Studying Munc13-2 Function

Molecular approaches:

• Recombinant protein expression
• Co-immunoprecipitation for interaction partners
• In vitro reconstitution assays
• Structural biology (X-ray crystallography, cryo-EM)

• Primary neuron culture
• Synaptosome preparations
• Astrocyte-neuron co-cultures
• iPSC-derived neurons

• Knockout mice (Munc13-2 null)
• Knock-in mice with specific mutations
• Conditional knockouts
• Transgenic overexpression

• Whole-cell patch clamp recordings
• Miniature excitatory/inhibitory postsynaptic currents (mEPSC/mIPSC)
• Paired-pulse facilitation/depression
• Evoked release measurements

Interaction Network

Munc13-2 interacts with multiple synaptic proteins:

| Interacting Protein | Interaction Type | Functional Significance |
|---------------------|-----------------|------------------------|
| Syntaxin-1 | Direct binding | SNARE complex formation |
| SNAP-25 | Indirect | SNARE complex formation |
| Synaptobrevin/VAMP | Indirect | SNARE complex formation |
| Munc18 | Direct binding | Vesicle priming |
| Complexin | Direct binding | Fusion clamp |
| Synaptotagmin-1 | Functional | Calcium sensing |
| RIM | Direct binding | Active zone organization |
| CABP | Direct binding | Calcium regulation |

Comparison with Other Munc13 Isoforms

| Isoform | Gene | C1 Domain | Expression | Function |
|---------|------|-----------|------------|----------|
| Munc13-1 | UNC13A | Yes | Very high | Major isoform |
| Munc13-2 | UNC13B | Yes/No (isoforms) | High | Plasticity modulation |
| Munc13-3 | UNC13C | Yes | Limited | Cerebellar function |

Future Directions

Unresolved Questions

Emerging Research Areas

• Super-resolution microscopy of Munc13-2
• Single-molecule imaging of priming events
• Patient-derived neurons for disease modeling
• High-throughput screening for modulators

Key Publications

External Resources

• [NCBI Gene: UNC13B](https://www.ncbi.nlm.nih.gov/gene/23026)
• [UniProt: Munc13-2 (Q9Y5S4)](https://www.uniprot.org/uniprot/Q9Y5S4)
• [OMIM: UNC13B (607698)](https://www.omim.org/entry/607698)
• [Ensembl: UNC13B](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000075643)
• [GeneCards: UNC13B](https://www.genecards.org/cgi-bin/carddisp.pl?gene=UNC13B)

See Also

Related Gene Pages

• [UNC13A — UNC13 Homolog A (Munc13-1)](/genes/unc13a) - Major Munc13 isoform
• [UNC13C — UNC13 Homolog C (Munc13-3)](/genes/unc13c) - Cerebellar isoform
• [STXBP1 — Syntaxin Binding Protein 1 (Munc18-1)] - Synaptic vesicle regulation
• [RIM1 — Rab3 Interacting Molecule](/genes/rim1) - Active zone protein

Related Mechanism Pages

• [Synaptic Vesicle Cycle](/mechanisms/synaptic-vesicle-cycle) - Vesicle dynamics
• [Neurotransmitter Release](/mechanisms/neurotransmitter-release) - Release machinery
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity) - Activity-dependent changes
• [SNARE Complex](/mechanisms/snare-complex) - Fusion machinery

Related Disease Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease) - Neurodegenerative disease
• [Parkinson's Disease](/diseases/parkinsons-disease) - Neurodegenerative disease
• [Epilepsy](/diseases/epilepsy) - Seizure disorder

Conclusion

UNC13B encodes Munc13-2, an essential presynaptic protein that serves as a master regulator of synaptic vesicle priming. Through its role in preparing synaptic vesicles for calcium-triggered fusion, Munc13-2 determines the fundamental release probability of synapses and shapes short-term plasticity patterns that underlie information processing in neural circuits.

The protein's distinctive architecture, including the MUN domain, C1 domain, and C2 domains, enables it to integrate multiple regulatory signals and modulate synaptic strength in response to neural activity. This regulatory capacity positions Munc13-2 at the intersection of synaptic signaling and plasticity, making it crucial for proper circuit function.

Dysfunction of Munc13-2 has been increasingly recognized in neurodegenerative and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and schizophrenia. The early involvement of synaptic dysfunction in these conditions makes Munc13-2 a promising therapeutic target for preserving synaptic function and preventing cognitive decline.

Understanding Munc13-2's detailed mechanisms and developing approaches to modulate its function remain active areas of research with significant implications for treating neurological disorders.